Prevalence of Undiagnosed Atrial Fibrillation and of That Not Being Treated With Anticoagulant Drugs: the AFABE Study
| Autor: | Albert Roso-Llorach, Nuria González-Rojas, Emmanuel Giménez-Garcia, Carles López-Pablo, Miquel Gallofré López, Josep Lluís Clua-Espuny, Jorgina Lucas-Noll, Anna Panisello-Tafalla, Ramón Bosch-Príncep, Iñigo Lechuga-Duran, Lluïsa Queralt-Tomas |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Male
medicine.medical_specialty Cross-sectional study medicine.drug_class Electrocardiography Internal medicine Atrial Fibrillation Antithrombotic Prevalence medicine Humans Aged Retrospective Studies HAS-BLED business.industry Anticoagulant Anticoagulants Retrospective cohort study Atrial fibrillation General Medicine Odds ratio Middle Aged medicine.disease Confidence interval Cross-Sectional Studies Spain Cardiology Female business |
| Zdroj: | Revista Española de Cardiología (English Edition). 66:545-552 |
| ISSN: | 1885-5857 |
| DOI: | 10.1016/j.rec.2013.03.003 |
| Popis: | Introduction and objectives: Atrial fibrillation constitutes a serious public health problem because it can lead to complications. Thus, the management of this arrhythmia must include not only its treatment, but antithrombotic therapy as well. The main goal is to determine the proportion of cases of undiagnosed atrial fibrillation and the proportion of patients not being treated with oral anticoagulants. Methods: A multicenter, population-based, retrospective, cross-sectional, observational study. In all, 1043 participants over 60 years of age were randomly selected to undergo an electrocardiogram in a prearranged appointment. Demographic data, CHA2DS2-VASc and HAS-BLED scores, international normalized ratio results, and reasons for not receiving oral anticoagulant therapy were recorded. Results: The overall prevalence of atrial fibrillation was 10.9% (95% confidence interval, 9.1%-12.8%), 20.1% of which had not been diagnosed previously. In the group with known atrial fibrillation, 23.5% of those with CHA2DS2-VASc≥2 were not receiving oral anticoagulant therapy, and 47.9% had a HAS-BLED score≥3. The odds ratio for not being treated with oral anticoagulation was 2.04 (95% confidence interval, 1.11-3.77) for women, 1.10 (95% confidence interval, 1.05-1.15) for more advanced age at diagnosis, and 8.61 (95% confidence interval 2.38-31.0) for a CHA2DS2-VASc score |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect